Casirivimab + imdevimab removed from NHS Commissioning Policy as omicron variant is not susceptible to the combination.- Regeneron + Roche
NICE: Do not offer a combination of casirivimab and imdevimab to people hospitalised because of COVID-19 who are known or suspected to have infection caused by an Omicron variant (or any other variant not susceptible to casirivimab and imdevimab).
In vitro data suggests that Omicron, the current dominant variant in England, is not susceptible to the combination of casirivimab and imdevimab. As of 24 February 2022, NHS England has removed casirivimab and imdevimab from their Interim Clinical Commissioning Policy and there is currently no access to this treatment in England.
Learning Zones
The Learning Zones are an educational resource for healthcare professionals that provide medical information on the epidemiology, pathophysiology and burden of disease, as well as diagnostic techniques and treatment regimens.
1 mins